08:52 AM EDT, 06/24/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) , up 2% in U.S. pre-market trading, having dropped near 6% in Canada yesterday, on Tuesday said the independent Data Safety Monitoring Board (DSMB) has raised no concerns after completing its third quarterly safety data review of the Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in metastatic breast cancer.

The DSMB recommended the study continue without modifications. BriaCell's Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration (FDA).

"The third consecutive DSMB review is a meaningful milestone in our Phase 3 trial, which continues to highlight the excellent safety and tolerability profile of BriaCell's regimen," said Dr. William Williams, chief executive officer. "This latest positive review further strengthens our confidence in Bria-IMT's potential as a transformative immunotherapy for patients with metastatic breast cancer."

BriaCell was last seen up US$0.06, to US$2.94, in New York trading. It was down 5.7% on the TSX yesterday.